Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8588222rdf:typepubmed:Citationlld:pubmed
pubmed-article:8588222lifeskim:mentionsumls-concept:C0031327lld:lifeskim
pubmed-article:8588222lifeskim:mentionsumls-concept:C0021081lld:lifeskim
pubmed-article:8588222lifeskim:mentionsumls-concept:C1720825lld:lifeskim
pubmed-article:8588222pubmed:issue6lld:pubmed
pubmed-article:8588222pubmed:dateCreated1996-3-22lld:pubmed
pubmed-article:8588222pubmed:abstractTextImmunosuppressive drug treatment has developed considerably in recent years with new methods describing pharmacokinetic-pharmacodynamic relationships. Using in vitro models it is possible to predict the success of clinical immunosuppressive drug combinations. Furthermore, with the advances of analytical methodology it is now possible to measure minute amounts of potent immunosuppressants and to adjust dosing based on concentration measurements. Concentration control, which first was required for cyclosporine A, is being investigated for most immunosuppressive drugs in development. Characterisation of individual drug pharmacokinetics form the basis for successful immunosuppression. Among possible therapeutic drug monitoring methodologies, trough level monitoring is currently the method of choice.lld:pubmed
pubmed-article:8588222pubmed:languageenglld:pubmed
pubmed-article:8588222pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8588222pubmed:citationSubsetIMlld:pubmed
pubmed-article:8588222pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8588222pubmed:statusMEDLINElld:pubmed
pubmed-article:8588222pubmed:monthDeclld:pubmed
pubmed-article:8588222pubmed:issn0163-4356lld:pubmed
pubmed-article:8588222pubmed:authorpubmed-author:LindholmAAlld:pubmed
pubmed-article:8588222pubmed:authorpubmed-author:SäweJJlld:pubmed
pubmed-article:8588222pubmed:issnTypePrintlld:pubmed
pubmed-article:8588222pubmed:volume17lld:pubmed
pubmed-article:8588222pubmed:ownerNLMlld:pubmed
pubmed-article:8588222pubmed:authorsCompleteYlld:pubmed
pubmed-article:8588222pubmed:pagination570-3lld:pubmed
pubmed-article:8588222pubmed:dateRevised2005-11-16lld:pubmed
pubmed-article:8588222pubmed:meshHeadingpubmed-meshheading:8588222-...lld:pubmed
pubmed-article:8588222pubmed:meshHeadingpubmed-meshheading:8588222-...lld:pubmed
pubmed-article:8588222pubmed:meshHeadingpubmed-meshheading:8588222-...lld:pubmed
pubmed-article:8588222pubmed:year1995lld:pubmed
pubmed-article:8588222pubmed:articleTitlePharmacokinetics and therapeutic drug monitoring of immunosuppressants.lld:pubmed
pubmed-article:8588222pubmed:affiliationDepartment of Clinical Pharmacology, Karolinska Institute, Huddinge Hospital, Sweden.lld:pubmed
pubmed-article:8588222pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8588222pubmed:publicationTypeReviewlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8588222lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8588222lld:pubmed